Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Tobacco smoke exposure is associated with diminished longitudinal benefit of elexacaftor/tezacaftor/ivacaftor in cystic fibrosis

Journal of Cystic Fibrosis(2025)10.1016/j.jcf.2025.05.002Source: DataRank Database

Tobacco smoke exposure is associated with diminished longitudinal benefit of elexacaftor/tezacaftor/ivacaftor in cystic fibrosis is a research paper published in Journal of Cystic Fibrosis (2025). On theSindex it has a DataRank of 0. It has been cited 6 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access6 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 4.48)OA: greenTopics (60)IDs (PubMed, PMC, OpenAlex)Annotations (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (6)

Elizabeth Baker ORCID,Jennifer S. Guimbellot ORCID,Joseph M. Collaco ORCID,Michael S. Schechter ORCID,Gabriela R. Oates ORCID

Live enrichment

PubMed:40506287 PMC:PMC12256006 OpenAlex:https://openalex.org/W4411199088

Cystic Fibrosis Foundation

Grant: GUIMBE22Y7

Cystic Fibrosis Foundation

Grant: HARRISG023

National Institute of Diabetes and Digestive and Kidney Diseases

Grant: P30DK72482

NIDDK NIH HHS

Grant: P30 DK072482

National Institutes of Health

FWCI

4.48

Citation Percentile

0.9%

Citation Trend

2026

greenLicense: http://www.elsevier.com/open-access/userlicense/1.0/

repositoryhttps://pubmed.ncbi.nlm.nih.gov/40506287/

publisherhttps://api.elsevier.com/content/article/PII:S1569199325014717?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1569199325014717?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.jcf.2025.05.002

Fields of Study

Cystic Fibrosis Research AdvancesNematode management and characterization studiesHumansCystic FibrosisMaleFemaleDrug CombinationsBenzodioxolesQuinolonesRetrospective StudiesAminophenolsLongitudinal StudiesIndolesPyridinesChloride Channel AgonistsTobacco Smoke PollutionAdultAdolescentChildPyrazolesRespiratory Function TestsPyrrolidinesYoung AdultQuinolines

MeSH Terms

AdolescentAdultAminophenolsChildCystic FibrosisDrug CombinationsFemaleHumansIndolesLongitudinal StudiesMalePyrazolesPyridinesPyrrolidinesQuinolinesRespiratory Function TestsRetrospective StudiesTobacco Smoke PollutionQuinolonesBenzodioxolesYoung AdultChloride Channel Agonists

Keywords

IvacaftorCystic fibrosisMedicineTobacco smokeSmokeInternal medicineEnvironmental healthCystic fibrosis transmembrane conductance regulatorTobaccoHealth DisparitiesSecondhand SmokeCftr ModulatorSmoke ExposureElexacaftor/Tezacaftor/Ivacaftor

Tobacco smoke exposure is associated with diminished longitudinal benefit of elexacaftor/tezacaftor/ivacaftor in cystic fibrosis

FAIR Checklist

Authors (6)

Funding (5 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)